Zymeworks, a early-stage biotech developing bispecific antibodies that target HER2 tumors, raised $59 million by offering 4.5 million shares at $13, the low end of the range of $13 to $16. Zymeworks plans to list on the NYSE under the symbol ZYME. Citi, Barclays and Wells Fargo Securities acted as lead managers on the deal.
The article Zymeworks prices IPO at $13, the low end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.